Prot#WP-0512-003: A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Funding

• DP Clinical, Inc. (Prot#WP-0512-003 AMD 3 // Prot#WP-0512-003 AMD 3)
• Woolsey Pharmaceuticals, Inc. (Prot#WP-0512-003 AMD 3 // Prot#WP-0512-003 AMD 3)